Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 152

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 146 147 148 149 150 151 < 152 > 153 154 155 156 157 158 .. 184 >> Следующая

ЛИТЕРАТУРА
1. Goodnight S. Anticoagulation therapy for the antiphospholipid syndrome. In; Vascular manifestations of systemic autoimmune diseases. Ed R.A. Asherson, R. Cervera. CRC Press Roca Ralton 2000; 563—570.
2. Cuadrado MJ. Treatment and monitoring of patients with antiphospholipid antibodies and
thrombotic history (Hughes syndrome). Curr Rheumatol Rep 2002; 4: 392.
3. Roubeu RAS. Treatment of the antiphospholipid syndrome. CurrOpin Rheumatol 2002; 14: 238— 242.
4. Ruiz-Irastorz.a G, Khamashta MA, Hughes GRV. Antiagregant and anticoagulant therapy in
SHS-OOO4.qxd 21.11.2006 16:56 Page 372
ЧУ-
Насонов Е.Л. Антифосфолипидный синдром.
systemic lupus erythematosus and Hughes dyn-drome. Lupus 2001; 10: 241—245.
5. Derksen RHM, de Groot Ph G, Nieuwenhuis HKM, Christiaens G, C.M.L. How to treat women with antiphospholipid antibodies in pregnancy. Ann Rheum Dis 2001; 60: 1—3.
6. Lockwood CJ, Schur PH. Monitoring and treatment of pregnant women with the antiphos-pholipid antibody syndrome. UpToDate 2002; 10, № 2.
7. Berman BL, Schur PH, Kaplan AA. Prognosis and therapy of the antiphospholipid antibody syndrome. UpToDate 2004; 11.3.
8. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003; 349:1177—1179.
9. Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004—3008.
10. Насонов ЕЛ. Современные подходы к профилактике и лечению антифосфолипидного синдрома. Терапевт. архив, 2003; 5: 83—88.
11. Petri M. Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Curr Rheumatol Report 2003; 5: 370— 373.
12. Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implication for patients management. Curr Opin Rheumatol 2001; 13: 341—344.
13. Costenbader KH, Liang MH. Practical and theoretical barriers to the prevention of accelerated atherosclerosis in systemic lupus erythemato-sus. Arthritis Research Therapy 2003; 5: 178— 179.
14. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus — proposed guidelines for risk factor management. Rheumatology 2004; 43: 7—12.
15. Asherson RA, Chan JK, Harris EN, et al. Anticardiolipin antibody, recurrent thrombosis and warfarin withdrawal. Ann Rheum Dis 1985; 44: 823.
16. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993.
17. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thromboembolism should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689—692.
18. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191.
19. Brunner HI, Chan W-S, Ginsberg JS, Feldman BM. Long-term anticoagulant is preferable for patients with antiphospholipid antibody syndrome. Result of a decision analysis. J Rheumatology 2002; 29: 490—501.
20. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12: 499—503.
21. Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001; 28: 2018—2024.
22. Zotz RB, Gerhardt A, Schart RE. Prediction, prevention, and treatment of venous thromboembolic disease in pregnant. Semin Thromb Hemost 2003; 29: 143—153.
23. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many test, too much conflicting data. Hematology 2002; 1: 353.
24. Hudson M, Herr A-L, Rauch J, et al. The presence of multiple prothrombotic risk factors is associated with a high risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003; 30: 2385—2391.
25. Wachl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Do the benefits outweight the risk? A decision analysis. Arch Intern Med 2000; 160: 2042—2048.
26. Malaviya AN, Mourou M. Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus. Lupus 2000; 9: 561—562.
27. Erkan D, Merrill JT, Yazici Y, et al. High Thrombosis rate after fetal loss in antiphospho-lipid syndrome: effective prophylaxis with aspirin. Arthr Rheum 2001; 44: 1466—1469.
28. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk
SHS-OOO4.qxd 21.11.2006 16:56 Page З7З'
ЧУ-
ГЛАВА 13. Антифосфолипидный синдром: профилактика, лечение и прогноз
factors and preventive treatment in antiphospho-lipid syndrome. Rheumatology (Oxford) 2002; 41: 924—929.
29. Решетняк ТМ, Мач ЭС, Александрова ЕН и соавт. Тромбо АСС в профилактике сосудистых нарушений при антифосфолипидном синдроме. Клин. медицина, 1999; 10: 30—34.
Предыдущая << 1 .. 146 147 148 149 150 151 < 152 > 153 154 155 156 157 158 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed